Please select the option that best describes you:
Would you consider addition of adjuvant Capecitabine to TDM-1 in a patient with residual disease after neoadjuvant therapy (TCHP) for biopsy proven HR- HER2 positive breast cancer if residual disease after mastectomy shows HR- HER2 negative disease?
Would adding an oral agent like Capecitabine for the triple negative to T-DM1be advisable?